Quick Takeaways
- Stuart A. Arbuckle has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $29,352,174.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Stuart A. Arbuckle
- Location
- Cambridge, MA
- Summary
- The estimated net worth of Stuart A. Arbuckle is at least $29,352,174 dollars as of 10 Feb 2026. Stuart A. Arbuckle is the EVP, COO of VERTEX PHARMACEUTICALS INC / MA and owns shares of VERTEX PHARMACEUTICALS INC / MA (VRTX) stock worth about $28.59M. Stuart A. Arbuckle is the Director of RHYTHM PHARMACEUTICALS, INC. and owns shares of RHYTHM PHARMACEUTICALS, INC. (RYTM) stock worth about $421.3K. Stuart A. Arbuckle is the Director of Praxis Precision Medicines, Inc. and owns shares of Praxis Precision Medicines, Inc. (PRAX) stock worth about $336.3K.
- Signature
- /s/ Alex Nemiroff, as Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Stuart A. Arbuckle and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: VERTEX PHARMACEUTICALS INC / MA ($28,594,582).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Stuart A. Arbuckle
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| VRTX | VERTEX PHARMACEUTICALS INC / MA | Evp, Coo | $28,594,582 | 01 Jul 2025 | ||
| RYTM | RHYTHM PHARMACEUTICALS, INC. | Director | $421,260 | 24 Jun 2025 | ||
| PRAX | Praxis Precision Medicines, Inc. | Director | $336,332 | 06 Feb 2026 | ||
| IMGN | ImmunoGen, Inc. | Director | $0 | 12 Feb 2024 | ||
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | Director | 05 Jan 2026 |
Insider Transactions Reported by Stuart A. Arbuckle:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.